Rohtesh S Mehta, MD MPH MS

Peer-Reviewed Articles

1. Aljawai YM, Ramdial JL, Rondon G, Smallbone P, Kebriaei P, Popat UR, Oran B, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Outcomes of Haploidentical vs Mismatched Unrelated Donor HCT with Post-Transplant Cyclophosphamide Prophylaxis. Blood Adv, 2025. e-Pub 2025. PMID: 40517414.
2. Mehta RS, Lee SJ, Gooley T, Thur L, Dahlberg A, Delaney C, Gyurkocza B, Vo P, Deeg HJ, Milano F. Long-term outcomes and quality of life with treosulfan-based conditioning in hematological malignancies. Blood Adv 9(11):2691-2694, 2025. e-Pub 2025. PMID: 39969207.
3. Mehta, RS, Choe, H, Saultz, J, Gong, Z, Sharma, P, Al-Juhaishi, T, Petitto, GS, Lazaryan, A, Singh, AK, Xue, E, Dimitrova, D, Hyder, M, McCurdy, SR, Im, A, Huber, BD, Aljawai, YM, Kanakry, JA, Milano, F, Kanakry, CG. Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. American journal of hematology 100(6):987-997, 2025. e-Pub 2025. PMID: 40071498.
4. Mehta RS, Schmidt G, Williams K, Patel SA, Schetelig J, Savani B, Askar M, Petersdorf E, Ringden O, Kanakry CG, Kanakry JA, Stefanski H, Arrieta-Bolanos E, Betts B, Benjamin C, Gadalla S, Wang T, Saultz J, Spellman S, Jurdi NE, Bolon YT, Lee SJ. Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations. Transplant Cell Ther, 2025. e-Pub 2025. PMID: 40419020.
5. Mehta RS, Aljawai YM, Al-Juhaishi T, Saultz J, Milano F, Kanakry JA, Kanakry CG, Lazaryan A. Role of Donor Cytomegalovirus Serostatus in Cytomegalovirus-Seronegative Recipients of Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis. Transplant Cell Ther, 2025. e-Pub 2025. PMID: 40379049.
6. Sharma R, Holtzman NG, Pusic I, Cutler CS, Treister N, Mehta RS, Alousi AS, Vigneswaran N, Javaid A, Boksa FA 4th, Mody DP, Costa-da-Silva AC, Schueller O, Mace S, Yao Y, Ji R, Hu B, Marshall K, Blazar BR, Lee SJ, Pavletic SZ, Mays JW. Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study. Blood Adv, 2025. e-Pub 2025. PMID: 40311075.
7. Smallbone, PI, Mehta, RS, Alousi, AM. Steroid Refractory Acute GVHD. American journal of hematology 100(S3):14-29, 2025. e-Pub 2025. PMID: 40123554.
8. Mehta RS. SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection. Clin Lymphoma Myeloma Leuk 24(12):821-826, 2024. e-Pub 2024. PMID: 38825445.
9. Carpenter PA, Gooley TA, Boiko JR, Lee CJ, Burroughs L, Mehta RS, Salit RB, Bhatt NS, Krakow EF, Dahlberg A, Yeh AC, Summers C, Ueda Oshima M, Petersdorf EW, Vo PT, Connelly-Smith L, Lee SJ. Decreasing Chronic Graft-Versus-Host Disease rates in all populations. Blood Adv 8(22):5829-5837, 2024. e-Pub 2024. PMID: 39167805.
10. Marcoux CM, Alousi AM, Im J, Hill LC, Smallbone P, Popat U, Hosing C, Kebriaei P, Olson A, Mehta R, Chen G, Qazilbash M, Shpall E, Champlin RC, Saliba RM. Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transplant 59(11):1594-1600, 2024. e-Pub 2024. PMID: 39187601.
11. Mehta RS, Ramdial JL, Kebriaei P, Champlin RE, Popat UR, Rezvani K, Shpall EJ. Haploidentical versus HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv 8(20):5306-5314, 2024. e-Pub 2024. PMID: 39167765.
12. Mehta RS, Petersdorf EW, Wang T, Spellman SR, Lee SJ. Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT. Blood Adv 8(20):5438-5449, 2024. e-Pub 2024. PMID: 39008717.
13. Hamilton BK, Carpenter PA, Pidala J, El Jurdi N, Farhadfar N, Kitko CL, Lee CJ, Mehta R, Chen GL, Cutler C, Lee SJ. Study Protocol: Predicting the Quality of Response to Specific Treatments (PQRST) in Chronic Graft-versus-Host Disease. Contemp Clin Trials 145:107637, 2024. e-Pub 2024. PMID: 39038701.
14. Hayase, E, Hayase, T, Mukherjee, A, Stinson, SC, Jamal, M, Ortega, MR, Sanchez, CA, Ahmed, S, Karmouch, J, Chang, C, Flores, I, McDaniel, L, Brown, AN, El-Himri, RK, Chapa, V, Tan, L, Tran, B, Xiao, Y, Fan, C, Pham, D, Halsey, T, Jin, Y, Tsai, W, Prasad, R, Glover, I, Enkhbayar, A, Mohammed, A, Schmiester, M, King, KY, Britton, RA, Reddy, P, Wong, M, Ajami, NJ, Wargo, J, Shelburne, S, Okhuysen, PC, Liu, C, Fowler, S, Conner, ME, Katsamakis, Z, Smith, N, Burgos da Silva, M, Ponce, DM, Peled, JU, van den Brink, MR, Peterson, CB, Rondon, G, Molldrem, JJ, Champlin, RE, Shpall, E, Lorenzi, PL, Mehta, RS, Martens, EC, Alousi, AM, Jenq, RR. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host and Microbe 32(9):1621-1636.e6, 2024. e-Pub 2024. PMID: 39214085.
15. Mehta RS, Petersdorf EW, Wang T, Lee SJ. Haploidentical Versus Mismatched Unrelated Donor Hematopoietic Cell Transplantation: HLA Factors and Donor Age Considerations. Transplant Cell Ther 30(9):909.e1-909.e11, 2024. e-Pub 2024. PMID: 38992469.
16. Banerjee R, Cowan AJ, Ortega M, Missimer C, Carpenter PA, Oshima MU, Salit RB, Vo PT, Lee CJ, Mehta RS, Kuderer NM, Shankaran V, Lee SJ, Su CT. Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma. Clin Lymphoma Myeloma Leuk 24(7):446-454.e3, 2024. e-Pub 2024. PMID: 38521640.
17. Saliba RM, Lee SJ, Carpenter PA, Hill GR, Lee CJ, Alousi A, Daher M, Chen G, Champlin RE, Rezvani K, Shpall EJ, RS||B M. Mycophenolate mofetil is associated with inferior overall survival in cytomegalovirus-seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Haematologica 109(7):2321-2325, 2024. e-Pub 2024. PMID: 38426274.
18. Ramdial J, Kebriaei P, Champlin RE, Popat U, Rezvani K, Shpall EJ, Mehta RS. Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis. Leukemia 38(6):1432-1434, 2024. e-Pub 2024. PMID: 38698071.
19. Salit RB, Lee SJ, Bhatt NS, Carpenter PA, Fan X, Armstrong A, Oshima MU, Connelly-Smith L, Krakow E, Lee CJ, Vo P, Mehta R, Syrjala KL. Returning to Work Following Hematopoietic Cell Transplantation: The Survivor's Perspective. Transplant Cell Ther 30(6):612.e1-612.e12, 2024. e-Pub 2024. PMID: 38561139.
20. Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, Rondon G, Kebriaei P, Champlin R, Daver N, Dinardo C, Short NJ, Shpall EJ, Oran B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 24(5):e196-e204, 2024. e-Pub 2024. PMID: 38403505.
21. Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant 59(5):699-704, 2024. e-Pub 2024. PMID: 38355908.
22. Mehta RS, Petersdorf EW, Spellman SR, Lee SJ. Combined effect of unrelated donor age and HLA peptide-binding motif match status on HCT outcomes. Blood Adv 8(9):2235-2242, 2024. e-Pub 2024. PMID: 38467032.
23. Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, Alousi AM, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson BS, Champlin RE, Popat UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol 99(4):562-569, 2024. e-Pub 2024. PMID: 38314663.
24. Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplant Cell Ther 30(2):205.e1-205.e12, 2024. e-Pub 2024. PMID: 37437764.
25. Saliba RM, Kanakry CG, Gadalla S, Kebriaei P, Rezvani K, Champlin RE, Shpall EJ, Weisdorf D, Mehta RS. Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol 99(1):38-47, 2024. e-Pub 2024. PMID: 37850688.
26. Axell-House DB, Nagarajan P, Bhatti MM, Mehta RS, Roy S, Ali IKM, John TM. Endophthalmitis, Cutaneous Nodules, and Brain Lesions in Stem Cell Transplant Recipient. Clin Infect Dis 77(8):1212-1215, 2023. e-Pub 2023. PMID: 37831593.
27. Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
28. Mehta RS. Pick Your Poison: Higher Risk of Relapse (older MSD) or A Higher Risk of Non-Relapse Mortality (younger MUD)?. Transplant Cell Ther 29(10):587-588, 2023. e-Pub 2023. PMID: 37827596.
29. Mehta RS, Ali H, Dai Y, Yao B, Overman B, Ratanatharathorn V, Gill S, Socié G, Anderson K, Cahn JY, Mujeebuddin A, Champlin R, Shpall E, Holtan SG, Alousi A. A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplant 58(9):991-999, 2023. e-Pub 2023. PMID: 37202544.
30. Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
31. Mehta RS, Ramdial J, Marin D, Alousi A, Kanakry CG, Champlin RE, Rezvani K, Shpall EJ, Page K, Gadalla SM, Kebriaei P, Weisdorf D. Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. Transplant Cell Ther 29(6):377.e1-377.e7, 2023. e-Pub 2023. PMID: 36990221.
32. Ostrin EJ, Rider NL, Alousi AM, Irajizad E, Li L, Peng Q, Kim ST, Bashoura L, Arain MH, Noor LZ, Patel N, Mehta R, Popat UR, Hosing C, Jenq RR, Rondon G, Hanash SM, Paczesny S, Shpall EJ, Champlin RE, Dickey BF, Sheshadri A. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. Immunohorizons 7(6):421-430, 2023. e-Pub 2023. PMID: 37289498.
33. Marcoux C, Marin D, Ramdial J, AlAtrash G, Alousi AM, Oran B, Kebriaei P, Popat UR, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Am J Hematol 98(5):712-719, 2023. e-Pub 2023. PMID: 36734029.
34. Mehta RS, Marin D, Alousi A, Kanakry CG, Champlin RE, Rezvani K, Shpall EJ, Page K, Gadalla SM, Weisdorf D, Kebriaei P. Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. Blood Adv 7(8):1594-1603, 2023. e-Pub 2023. PMID: 36630564.
35. Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Ost DE, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri A. Risk factors for bronchiolitis obliterans syndrome after initial detection of pulmonary impairment. Transplant Cell Ther 29(3):204.e1-204.e7, 2023. e-Pub 2023. PMID: 36503180.
36. Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2023. PMID: 36470579.
37. Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant. JCO Oncol Pract 19(3):e417-e427, 2023. e-Pub 2023. PMID: 36626702.
38. Hayase E, Hayase T, Mukherjee A, Stinson SC, Jamal MA, Ortega MR, Sanchez CA, Ahmed SS, Karmouch JL, Chang CC, Flores II, McDaniel LK, Brown AN, El-Himri RK, Chapa VA, Tan L, Tran BQ, Pham D, Halsey TM, Jin Y, Tsai WB, Prasad R, Glover IK, Ajami NJ, Wargo JA, Shelburne S, Okhuysen PC, Liu C, Fowler SW, Conner ME, Peterson CB, Rondon G, Molldrem JJ, Champlin RE, Shpall EJ, Lorenzi PL, Mehta RS, Martens EC, Alousi AM, Jenq RR. Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq, 2023. e-Pub 2023. PMID: 36778495.
39. Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med 14(671):eabo3445, 2022. e-Pub 2022. PMID: 36383683.
40. Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. Myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA matched and haploidentical transplantation: results of a phase II study. Haematologica 107(10):2496-2500, 2022. e-Pub 2022. PMID: 35770531.
41. Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
42. Meyer E, Pavlova A, Gandhi A, Hoeg R, Oliai C, Mehta R, Srour S, McGuirk J, Waller E, Fernhoff N, Killian MS, Mcclellan J, Putnam A, Shaw B, Abedi M, Negrin R. CT-524 Orca-T, A Precision Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S447, 2022. e-Pub 2022. PMID: 36164225.
43. Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
44. Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
45. Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
46. Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. Blood 139(12):1908-1919, 2022. e-Pub 2022. PMID: 34914826.
47. Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved Outcomes Among Newly Diagnosed Patients with FLT3-ITD Mutated AML Treated with Contemporary Therapy: Revisiting the ELN Adverse Risk Classification. Am J Hematol 97(3):329-337, 2022. e-Pub 2022. PMID: 34981570.
48. Sheshadri A, Makhnoon S, Alousi AM, Bashoura L, Andrade R, Miller CJ, Stolar KR, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Taylor MS, Stenzler A, Mehta R, Popat UR, Hosing C, Ost DE, Champlin RE, Dickey BF, Peterson SK. Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability. JMIR Form Res 6(2):e29393, 2022. e-Pub 2022. PMID: 35129455.
49. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):257-262, 2022. e-Pub 2022. PMID: 34135465.
50. Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia 36(1):298, 2022. e-Pub 2022. PMID: 34876697.
51. Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
52. Cutler CS, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta RS, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin JP, Im A, Langston A, Liesveld JL, Juckett M, Logan A, Schachter L, Alavi A, Howard DS, Waksal H, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green LS, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic SZ. Belumosudil for Chronic Graft-versus-Host Disease (cGVHD) After 2 or More Prior Lines of Therapy: The ROCKstar Study. Blood 138(22):2278-2289, 2021. e-Pub 2021. PMID: 34265047.
53. Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Graft for Haploidentical HCT with Post Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
54. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
55. Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer S, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. 9-year follow-up of patients with relapsed follicular lymphoma after nonmyeloablative allogeneic stem cell transplant and autologous transplant. Clin Cancer Res 27(21):5847-5856, 2021. e-Pub 2021. PMID: 34380640.
56. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
57. Mehta R, Torres Cabala CA, DiNardo CD, Daver N, Dabaja B, Rezvani K, Champlin RE, Shpall E, Duvic M. Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant Hemophagocytic lymphohistiocytosis. Am J Hematol 96(9):E350-E353, 2021. e-Pub 2021. PMID: 34096089.
58. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):JCO2002608, 2021. e-Pub 2021. PMID: 33929874.
59. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648-2656, 2021. e-Pub 2021. PMID: 33793964.
60. Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
61. Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant 56(8):2005-2012, 2021. e-Pub 2021. PMID: 33846563.
62. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(7):1746-1749, 2021. e-Pub 2021. PMID: 33767403.
63. Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece IK, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood 138(3):273-282, 2021. e-Pub 2021. PMID: 34292325.
64. Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AM. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant 56(6):1316-1324, 2021. e-Pub 2021. PMID: 33398094.
65. Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
66. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193(3):e23-e26, 2021. e-Pub 2021. PMID: 33748943.
67. Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat UR. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 127(10):1598-1605, 2021. e-Pub 2021. PMID: 33471943.
68. Merino AM, Mehta RS, Luo X, Kim H, De For T, Janakiram M, Cooley S, Wangen R, Cichocki F, Weisdorf DJ, Miller JS, Bachanova V. Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma. Transplant Cell Ther 27(4):310.e1-310.e6, 2021. e-Pub 2021. PMID: 33836870.
69. Gooptu M, Romee R, St Martin A, Arora M, Al Malki MM, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece I, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M. HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood. e-Pub 2021. PMID: 33851205.
70. Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
71. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther 27(3):272.e1-272.e5, 2021. e-Pub 2021. PMID: 33781539.
72. Sheshadri A, Saliba R, Patel B, Ahmed T, Bueno LC, Arain MH, Mehta RS, Popat UR, Hosing CM, Rondon G, Bashoura L, Dickey BF, Champlin RE, Alousi AM. Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplant 56(3):745-748, 2021. e-Pub 2021. PMID: 33009515.
73. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. e-Pub 2021. PMID: 33637601.
74. Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, Battiwalla M, Bredeson CN, Copelan E, Cutler CS, George BR, Gupta V, Kanakry C, Mehta RS, Milano F, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Weisdorf DJ, Eapen M. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv 5(4):975-983, 2021. e-Pub 2021. PMID: 33576783.
75. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 144(1):1-8, 2021. e-Pub 2021. PMID: 32604096.
76. Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations. Am J Hematol 95(11):E313-E315, 2020. e-Pub 2020. PMID: 32804409.
77. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
78. Sheshadri A, Alousi A, Bashoura L, Stolar K, Baghaie S, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Peterson SK, Langhals R, Taylor M, Stenzler A, Mehta RS, Popat UR, Hosing C, Rondon G, Shen F, Li L, Cheng GS, Ost DE, Champlin RE, Dickey BF. Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. Ann Am Thorac Soc 17(10):1329-1333, 2020. e-Pub 2020. PMID: 32614241.
79. Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for HCT in Myelofibrosis: Long-term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
80. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, Ahmed I, Al-Homsi AS, Aljurf M, Antin JH, Askar M, Auletta JJ, Bhatt VR, Chee L, Chhabra S, Daly A, DeFilipp Z, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Hogan WJ, Inamoto Y, Martino R, Majhail NS, Marks DI, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Rangarajan HG, Ringden O, Saad A, Savani BN, Schoemans H, Seo S, Schultz KR, Solh M, Spitzer T, Storek J, Teshima T, Verdonck LF, Wirk B, Yared JA, Cahn JY, Weisdorf DJ. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol 38(18):JCO1900396, 2020. e-Pub 2020. PMID: 32364845.
81. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 126(10):2193-2205, 2020. e-Pub 2020. PMID: 32125707.
82. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion After Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
83. Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
84. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE. Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?. Blood 135(6):449-452, 2020. e-Pub 2020. PMID: 31826244.
85. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
86. Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 26(1):197-203, 2020. e-Pub 2020. PMID: 31518645.
87. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
88. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
89. Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PP, Shaim H, Daher M, Basar R, Imahashi N, Jimenez J, Hu B, Mehta RS, Kerbauy LN, Kaplan M, Mendt M, Ozcan G, Gokdemir E, Hernandez Sanabria M, Li Y, Chen K, Wang J, Muniz-Feliciano L, Zhao WL, Champlin RE, Shpall EJ, Rezvani K. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv 3(23):4117-4130, 2019. e-Pub 2019. PMID: 31821460.
90. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica 104(12):e555-e557, 2019. e-Pub 2019. PMID: 30948491.
91. Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. Leuk Lymphoma 60(14):1-8, 2019. e-Pub 2019. PMID: 31282244.
92. Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma 60(13):1-4, 2019. e-Pub 2019. PMID: 31246142.
93. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
94. Oran B, Champlin RE, Wang F, Jeyakumar N, Garcia-Manero G, Kantarjian HM, Saliba RM, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood 134(Supplement_1):47, 2019. e-Pub 2019. PMID: 31723997.
95. Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. Blood 134(Supplement_1):42, 2019. e-Pub 2019. PMID: 31724003.
96. Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk 19(9):560-569, 2019. e-Pub 2019. PMID: 31201134.
97. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. e-Pub 2019. PMID: 31296578.
98. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 54(7):1089-1093, 2019. e-Pub 2019. PMID: 30446740.
99. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
100. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Adv 3(9):1441-1449, 2019. e-Pub 2019. PMID: 31053571.
101. Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant 25(3):505-514, 2019. e-Pub 2019. PMID: 30308325.
102. Mehta RS, Rezvani K, Shpall EJ. Cord Blood Expansion: A Clinical Advance. J Clin Oncol 37(5):363-366, 2019. e-Pub 2019. PMID: 30576267.
103. Mehta RS, Oran B. The Optimal Killer Cell Immunoglobulin-Like Receptor Donor-We Can Recognize, but Can We Search?. Biol Blood Marrow Transplant 25(1):e3-e4, 2019. e-Pub 2019. PMID: 30472435.
104. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. e-Pub 2018. PMID: 30389035.
105. Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE. Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Adv 2(17):2254-2261, 2018. e-Pub 2018. PMID: 30206098.
106. Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood 131(26):2989-2992, 2018. e-Pub 2018. PMID: 29769261.
107. Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, Mehta RS, Warlick E, Cooley SA, Blazar BR, Miller JS, Weisdorf D, Wagner JE, Verneris MR. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv 2(8):909-922, 2018. e-Pub 2018. PMID: 29678809.
108. Mehta RS, Randolph B, Daher M, Rezvani K. NK cell therapy for hematologic malignancies. Int J Hematol 107(3):262-270, 2018. e-Pub 2018. PMID: 29383623.
109. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2018. PMID: 29269797.
110. Hill L, Alousi A, Kebriaei P, Mehta R, Rezvani K, Shpall E. New and emerging therapies for acute and chronic graft versus host disease. Ther Adv Hematol 9(1):21-46, 2018. e-Pub 2018. PMID: 29317998.
111. Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol 9:2444, 2018. e-Pub 2018. PMID: 30405633.
112. Mehta RS, Rezvani K. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer. Front Immunol 9:283, 2018. e-Pub 2018. PMID: 29497427.
113. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant 23(8):1359-1366, 2017. e-Pub 2017. PMID: 28506845.
114. Mehta RS, Cao Q, Holtan S, MacMillan ML, Weisdorf DJ. Upper GI GVHD: similar outcomes to other grade II graft-versus-host disease. Bone Marrow Transplant 52(52):1180-1186, 2017. e-Pub 2017. PMID: 28504665.
115. Jain S, Enzerra M, Mehta RS, Smith R, Djokic M. Bone marrow biopsies performed by both the powered OnControl drill device and the Jamshidi needle produce adequate specimens. J Clin Pathol 70(6):541-543, 2017. e-Pub 2017. PMID: 28062659.
116. Khoder A, Alsuliman A, Basar R, Sobieski C, Kondo K, Alousi AM, Szydlo R, Muftuoglu M, Shaim H, Apperley JF, Gokdemir E, Cooper N, Mehta RS, Marin D, Champlin R, Shpall E, Rezvani K. Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. Front Immunol 8:1937, 2017. e-Pub 2017. PMID: 29375566.
117. Mehta RS, Dave H, Bollard CM, Shpall EJ. Engineering cord blood to improve engraftment after cord blood transplant. Stem Cell Investig 4:41, 2017. e-Pub 2017. PMID: 28607915.
118. Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, Saltarrelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K. KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood 128(24):2819-2823, 2016. e-Pub 2016. PMID: 27760759.
119. Mehta RS, Rezvani K. Can we make a better match or mismatch with KIR genotyping?. Hematology Am Soc Hematol Educ Program 2016(1):106-118, 2016. e-Pub 2016. PMID: 27913469.
120. Mehta RS, Rezvani K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence 7(8):1-16, 2016. e-Pub 2016. PMID: 27385018.
121. Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood 128(10):1346-61, 2016. e-Pub 2016. PMID: 27439912.
122. Mehta RS, Peffault de Latour R, DeFor TE, Robin M, Lazaryan A, Xhaard A, Bejanyan N, de Fontbrune FS, Arora M, Brunstein CG, Blazar BR, Weisdorf DJ, MacMillan ML, Socie G, Holtan SG. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. Haematologica 101(6):764-72, 2016. e-Pub 2016. PMID: 27036159.
123. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SO. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 173(3):444-55, 2016. e-Pub 2016. PMID: 26947769.
124. Mehta RS, Chen X, Antony J, Boyiadzis M, Szabolcs P. Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts. J Immunother 39(2):71-80, 2016. e-Pub 2016. PMID: 26849076.
125. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica 100(10):1361-70, 2015. e-Pub 2015. PMID: 26250579.
126. Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly RF, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant 21(7):1284-90, 2015. e-Pub 2015. PMID: 25708219.
127. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
128. Zhou A, Mehta RS, Smith RE. Outcomes of platelet transfusion in patients with thrombotic thrombocytopenic purpura: a retrospective case series study. Ann Hematol 94(3):467-72, 2015. e-Pub 2015. PMID: 25288377.
129. Mehta RS, Shpall EJ, Rezvani K. Cord Blood as a Source of Natural Killer Cells. Front Med (Lausanne) 2:93, 2015. e-Pub 2015. PMID: 26779484.
130. Mehta RS, Rezvani K, Olson A, Oran B, Hosing C, Shah N, Parmar S, Armitage S, Shpall EJ. Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. Front Med (Lausanne) 2:89, 2015. e-Pub 2015. PMID: 26697430.
131. Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi A, O'Brien S, Wierda W, Keating M, Shpall EJ. Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk 14(3):e105-9, 2014. e-Pub 2014. PMID: 24502832.
132. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2014. e-Pub 2014. PMID: 24169268.
133. Mehta RS, Liman AD, Passero VA, Liman AK. Lung cancer with gastrointestinal metastasis - review of theories of metastasis with three rare case descriptions. Cancer Microenviron 6(3):203-11, 2013. e-Pub 2013. PMID: 23963996.
134. Mehta RS, Smith RE. Hemophagocytic lymphohistiocytosis (HLH): a review of literature. Med Oncol 30(4):740, 2013. e-Pub 2013. PMID: 24105023.
135. Mehta RS, Carty SE, Ohori NP, Hodak SP, Coyne C, LeBeau SO, Tublin ME, Stang MT, Johnson JT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L. Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology. Surgery 154(4):730-6; discussion 736-8, 2013. e-Pub 2013. PMID: 24074409.
136. Rollins-Raval M, Pillai R, Warita K, Mitsuhashi-Warita T, Mehta R, Boyiadzis M, Djokic M, Kant JA, Roth CG. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Appl Immunohistochem Mol Morphol 21(3):212-7, 2013. e-Pub 2013. PMID: 22914610.
137. Mehta RS, Ragni MV, Novelli EM. Chest pain, dyspnea, petechiae, and melena in a 58-year-old woman - what is it?. Platelets 24(5):415-8, 2013. e-Pub 2013. PMID: 22738440.
138. Chwistek M, Mehta RS. Vertebroplasty and kyphoplasty for vertebral compression fractures #202. J Palliat Med 15(10):1151-2, 2012. e-Pub 2012. PMID: 22957679.
139. Mehta RS, Ennis P, Whitten J. Ureterosigmoidostomy associated signet ring colon cancer presenting as hip pain. J Gastrointest Cancer 43(1):122-7, 2012. e-Pub 2012. PMID: 20625853.
140. Mehta RS, Lenzner D, Argiris A. Race and health disparities in patient refusal of surgery for early-stage non-small cell lung cancer: a SEER cohort study. Ann Surg Oncol 19(3):722-7, 2012. e-Pub 2012. PMID: 21947698.
141. Arnold RM, Miller M, Mehta RS. Insomnia: drug therapies #105. J Palliat Med 15(2):243-4, 2012. e-Pub 2012. PMID: 22339330.
142. Arnold RM, Miller M, Mehta RS. Insomnia: nonpharmacologic treatments #104. J Palliat Med 15(2):242-3, 2012. e-Pub 2012. PMID: 22339329.
143. Arnold RM, Miller M, Mehta R. Insomnia: patient assessment #101. J Palliat Med 15(1):124-6, 2012. e-Pub 2012. PMID: 22268410.
144. Mehta RS, Arnold RM. Management of spinal cord compression #238. J Palliat Med 14(3):362-3, 2011. e-Pub 2011. PMID: 21361838.
145. Mehta RS, Arnold RM. Evaluation of spinal cord compression #237. J Palliat Med 14(3):361-2, 2011. e-Pub 2011. PMID: 21361837.
146. Mehta RS, Arnold R. Evaluation of Spinal Cord Compression #237. J Palliat Med. e-Pub 2011. PMID: 21265630.
147. Yeow ME, Mehta RS, White DB, Szmuilowicz E. Using noninvasive ventilation at the end of life #230. J Palliat Med 13(9):1149-50, 2010. e-Pub 2010. PMID: 20836641.
148. Mehta RS. Novel oral anticoagulants. Part II: direct thrombin inhibitors. Expert Rev Hematol 3(3):351-61, 2010. e-Pub 2010. PMID: 21082985.
149. Mehta RS. Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). Expert Rev Hematol 3(2):227-41, 2010. e-Pub 2010. PMID: 21083465.
150. Mehta RS. Jejunal intussusception as an unusual cause of abdominal pain in an adult. Mcgill J Med 12(1):28-30, 2009. e-Pub 2009. PMID: 19753284.
151. Levy MH, Chwistek M, Mehta RS. Management of chronic pain in cancer survivors. Cancer J 14(6):401-9, 2008. e-Pub 2008. PMID: 19060605.
152. Mehta RS, Mikhail M. Post-irradiation cutaneous angiosarcoma. Cases J 1(1):241, 2008. e-Pub 2008. PMID: 18925942.
153. Mehta RS, Negin B, Popii V, Langer C. An aggressive radio-resistant papillary thyroid cancer. Clin Adv Hematol Oncol 6(10):761-7, 2008. e-Pub 2008. PMID: 18997667.
154. Mehta RS, Chwistek M. Bisphosphonates and osteonecrosis of the jaw #196. J Palliat Med 11(7):1039-40, 2008. e-Pub 2008. PMID: 18788967.
155. Mehta RS, Modi N, Sapanara N, Ramachandra P, Mikhail M. Extranodal marginal zone B-cell mucosa-associated lymphoid tissue (MALT) lymphoma of cecum presenting as bright red bleed per rectum--a case report with review of literature. J Gastrointest Cancer 39(1-4):66-72, 2008. e-Pub 2008. PMID: 19225911.

Editorials

1. Rafei H, Mehta RS, Rezvani K. Cellular Therapies in Cancer. Front Immunol 10:2788, 2019. PMID: 31827476.

Abstracts

1. Ramdial JL, Clemente-Sevilla L, Soebbing D, Dabaja BS, Thall PF, Alatrash G, Alousi AM, Mehta RS, Popat UR, Kebriaei P, Oran B, Rezvani K, Shpall EJ, Champlin RE. A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies. 64th ASH Annual Meeting and Exposition 140(Supplement 1):7484–7485, 2022. e-Pub 2022.
2. Yeh J, Saliba RM, Wang C, Fang Z, Figgins B, Ahmed S, Yilmaz M, Daver N, Mehta RS, Alatrash G, Marin D, Popat UR, Champlin RE, Shpall EJ, Oran B. Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia. 64th ASH Annual Meeting and Exposition 140(Supplement 1):7686–7688, 2022. e-Pub 2022.
3. Oran B, Champlin RE, Thall PF, McMcarty JM, Zhang W, Marin D, Mehta RS, Alousi AM, Alatrash G, Popat UR, Kantarjian H, Bashir Q, Shpall EJ, Konopleva M. Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT). 64th ASH Annual Meeting and Exposition 140(Supplement 1):10561–10562, 2022. e-Pub 2022.
4. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. 64th ASH Annual Meeting and Exposition 140(Supplement 1):10530–10531, 2022. e-Pub 2022.
5. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. 64th ASH Annual Meeting and Exposition 140(Supplement 1):4880–4881, 2022. e-Pub 2022.
6. Pasvolsky O, Saliba RM, Popat UR, Alousi AM, Mehta RS, Yeh J, Alatrash G, Masood A, Ramdial JL, Rondon G, Kebriaei P, Champlin RE, Shpall EJ, Oran B. Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome. 64th ASH Annual Meeting and Exposition 140(Supplement 1):10550-10551, 2022. e-Pub 2022.
7. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. 64th ASH Annual Meeting and Exposition 140(Supplement 1):7649–7650, 2022. e-Pub 2022.
8. Maiti A, DiNardo CD, Ohanian M, Pemmaraju N, Daver N, Borthakur G, Ravandi F, Issa GC, Garcia-Manero G, Jain N, Kadia TM, Masarova L, Wierda WG, Yilmaz M, Alvarado Y, Jabbour E, Short N, Takahashi K, Loghavi S, Patel KP, Montalbano K, Pierce SA, Blivins CA, Mehta RS, Alatrash G, Popat UR, Kebriaei P, Oran B, Shpall EJ, Champlin RE, Kantarjian H, Konopleva M. Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial. 64th ASH Annual Meeting and Exposition 140(Supplement 1):7725–7728, 2022. e-Pub 2022.
9. Oliai C, Hoeg RT, Pavlova A, Gandhi A, Muffly L, Mehta RS, Srour SA, Waller EK, Lowsky R, Patel SS, Dholaria B, Bachier C, Pantin JM, Salhotra A, McGuirk J, Fernhoff NB, McClellan S, Abedi M, Negrin RS, Meyer E. Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity. 64th ASH Annual Meeting and Exposition 140(Supplement 1):654–656, 2022. e-Pub 2022.
10. Ozcan G, Popat UR, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Mehta RS, Ramdial JL, Rondon G, Shpall EJ, Champlin RE, Oran B. Transplant Outcomes for TP53 AML and MDS in a Contemporary Era. 64th ASH Annual Meeting and Exposition 140(Supplement 1):10620–10621, 2022. e-Pub 2022.
11. Pavlova A, Hoeg R, Gandhi A, Muffly L, Shiraz P, Oliai C, Mehta RS, Srour SA, McGuirk JP, Waller EK, Arai S, Johnston L, Lowsky R, Rezvani AR, Weng WK, Miklos DB, Frank MJ, Tamaresis J, Agrawal V, Fernhoff N, Bauer G, Putnam A, McClellan JS, Shaw BE, Abedi M, Negrin RS, Meyer EH. Orca-T Demonstrates Encouraging Overall Survival, Gvhd Reduction, and Tolerability in Patients with Hematologic Malignancies. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S319–S320, 2022. e-Pub 2022.
12. Kawedia JD, Liu X, Ramdial J, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini NY, Kebriaei P, Knape C, Gulbis AM, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Captisol-Enabled Melphalan (Evomela) Pharmacokinetics between Short and Long Infusion Arms in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S461-S462, 2022. e-Pub 2022.
13. Popat UR, Mehta RS, Thall P, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, ieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S78-S79, 2022. e-Pub 2022.
14. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, VAldez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S293, 2022. e-Pub 2022.
15. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis AM, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S82-S83, 2022. e-Pub 2022.
16. Srour SA, Mehta RS, Shah N, Qazilbash MH, Im J, Bashir Q, Saini N, Nieto Y, Khouri IF, Daher M, Kebriaei P, Popat UR, Manasanch EE, Lee HC, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Rezvani K. Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan f. 2022 ASCO Annual Meeting 40(Suppl 16):abstr 8009, 2022. e-Pub 2022.
17. Ong F, Ravandi F, Popat UR, Kadia TM, Daver NG, Dinardo CD, Konopleva M, Borthakur G, Shpall EJ, Oran B, Alatrash G, Mehta RS, Jabbour E, Yilmaz M, Issa GC, Garcia-Manero G, Maiti A, Abbas H, Champlin RE, Short J. Impact of induction approach on post-stem cell transplant (SCT) outcomes in older adults with newly diagnosed acute myeloid leukemia (AML). 2022 ASCO Annual Meeting 40(Suppl 16):abstr 7038, 2022. e-Pub 2022.
18. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S83-S84, 2022. e-Pub 2022.
19. Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Liu X, Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. 63rd ASH Annual Meeting and Exposition 138(Supplement 1):3941, 2021. e-Pub 2021.
20. Popat UR, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. 63rd ASH Annual Meeting and Exposition 138(Supplement 1):556, 2021. e-Pub 2021.
21. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. 63rd ASH Annual Meeting and Exposition 138(Supplement 1):1802, 2021. e-Pub 2021.
22. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash M, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. 63rd ASH Annual Meeting and Exposition 138(Supplement 1):1803, 2021. e-Pub 2021.
23. Al-Juhaishi T, Malek AE, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi A, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich V, Ahmed S. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. 63rd ASH Annual Meeting and Exposition 138(Supplement 1):1779, 2021. e-Pub 2021.
24. Hoeg RT, Moroz A, Gandhi A, Muffly L, Shiraz P, Oliai C, Mehta RS, Srour SA, McGuirk JP, Waller EK, Arai S, Johnston LJ, Lowsky R, Rezvani AR, Weng WK, Miklos DB, Frank MJ, Tamaresis J, Lu Y, Agrawal V, Fernhoff NB, Bauer G, Putnam A, McClellan JS, Shaw BE, Abedi M, Negrin RS, Meyer EH. Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study. 63rd ASH Annual Meeting and Exposition 138(Supplement 1):98, 2021. e-Pub 2021.
25. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. 63rd ASH Annual Meeting and Exposition 138(Supplement 1):2879, 2021. e-Pub 2021.
26. Mehta RS, Bassett R, Olson A, Chen J, Ganesh C, Alousi A, Anderlini P, Al-Atrash G, Bashir Q, Ciurea S, Hosing C, Im J, Kebriaei P, Khouri I, Marin D, Molldrem J, Nieto Y, Oran B, Rezvani K, Qazilbash M, Srour S, Shpall E, Champlin R, Andersson B, Popat U. Post-Transplant Cyclophosphamide in HLA-Matched and Haploidentical Transplant Recipients Receiving a Myeloablative Fractionated Busulfan Conditioning Regimen: Results of a Phase II Study. 2021 SOHO Annual Meeting 21(Supplemental 1):S258, 2021. e-Pub 2021.
27. Oran B, Ciurea SO, Kebriaei P, Mehta RS, Popat UR, Hosing C, McCarty JM, Hindman B, Messahel B, Champlin RE. Safety, Tolerability and Efficacy of Crenolanib Administered Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Patients with FLT3 Mutant AML, 2020. e-Pub 2020.
28. Oran B, Alousi AM, Mehta RS, Marin D, Kebriaei P, Popat UR, OLson AL, McCarty JM, Ramos JD, Bassett R, Keer HN, Thall PF, Champlin RE. Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):10-11, 2020. e-Pub 2020.
29. Saberian C Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Daher M, Gruschkus SK, Knape C, Whited L, Gulbis A, Marcotulli M, Rondon G, Popat UR, Mehta RS, Konopleva M, Oran B, Ohanian M, Ravandi F, Garcia-Manero G, Alousi AM, Daver N, Champlin RE, Diab A, Alatrash G. Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):1, 2020. e-Pub 2020.
30. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Hosing C, Ciurea SO, Daher M, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Kaufman GP, Patel KK, Shpall EJ, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):24-25, 2020. e-Pub 2020.
31. Oran B, Alatrash G, Alousi AM, Mehta RS, Hosing C, Popat UR, Im JS, McCarty JM, Ramos JD, Keer HN, Thall PF, Champlin RE. Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):29-30, 2020. e-Pub 2020.
32. Oran B, Ciurea SO, Mehta RS, Alousi AM, Rondon G, Popat UR, Marin D, Daher M, Im JS, Kebriaei P, Alatrash G, Champlin RE. Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):20-21, 2020. e-Pub 2020.
33. Saini N, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Srour SA, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):9-10, 2020. e-Pub 2020.
34. Khouri IF, Gruschkus SK, Gulbis A, Ledesma C, Jain N, Kadia TM, Pemmaraju N, Anderlini P, Bashir Q, Daher M, Kebriaei P, Marin D, Mehta R, Popat UR, Saini N, Srour SA, Im JS, Fayad L, Nair R, Iyer SP, Strati P, Samaniego F, Nastoupil LJ, Flowers C, Rondon G, Kantarjian HM, Champlin RE, Jabbour E. Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):10-12, 2020. e-Pub 2020.
35. Mukherjee A, Milton DR, Jabbour E, Daver N, Gulbis A, Ledesma G, Konopleva M, DiNardo CD, Ravandi F, Kadia TM, Alatrash G, Alousi AM, Daher M, Marin D, Olson AL, Oran B, Kebriaei P, Saini N, Srour SA, Popat UR, Im JS, |Mehta R, Rondon G, Kantarjian HM, Champlin RE, Khouri IF. Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):13-14, 2020. e-Pub 2020.
36. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Alatrash G, Bashir Q, Ciurea S, Hosing C, Im JS, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):10-11, 2020. e-Pub 2020.
37. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Hosing C, Patel KK, Lee HC, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):23-24, 2020. e-Pub 2020.
38. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Rondon G, Nieto Y, Ciurea S, Oran B, Im JS, Olson AL, Marin D, Qazilbash MH, Khouri IF, Anderlini P, Rezvani K, Popat UR, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):39-40, 2020. e-Pub 2020.
39. Khouri IF, Gruschkus SK, Ledesma C, Anderlini P, Bashir Q, Daher M, Iyer SP, Marin D, Mehta R, Olson AL, Popat UR, Samaniego F, Qazilbash MH, Im JS, Rondon G, Champlin RE, Gulbis A, Young KH. Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):24-25, 2020. e-Pub 2020.
40. Gooptu M, St Martin A, Romee R, Arora M, Al Malki MM, Jh A, Bredeson C, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Inamoto Y, Kanakry CG, Kekre N, Jp M, McNiece IK, Mehta RS, Mielcarek ML, Milano F, Modi D, Reshef R, Schroeder MA, Soiffer RJ, Solomon SR, Waller EK, Eapen M. Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. 62nd ASH Annual Meeting and Exposition 136(Supplement 1):21-22, 2020. e-Pub 2020.
41. Joseph J, Milton D, Al-Atrash G, Alousi A, Bashir Q, Daher M, Im J, Mehta R, Olson A, Oran B, Saini N, Srour S, Prithviraj B, Pemmaraju N, Verstovsek S. Myeloablative Fludarabine and Busulfan Regimen in Myelofibrosis (MF): Long-Term Outcomes and Analysis of Prognostic Factors. 2020 SOHO Virtual Meeting 20 Suppl 1:S333, 2020. e-Pub 2020.
42. Saberian C, Abdel-Wahab N, Abudayyeh A, Raafei H, Joseph J, Daher M, Gruschkus S, Knape C, Whited L, Gulbis A, Cornelison-Marcotulli M, g R, Popat U, Mehta R, Konopleva M, Oran B, Ohanian M, Ravandi F, Garacia-Manero G, Alousi A, Daver N, Champlin R, Diab A, Al-Atrash G. Post-Transplant Cyclophosphamide. 2020 SOHO Virtual Meeting 20 Suppl 1:S201-S202, 2020. e-Pub 2020.
43. Yalniz F, Saiba R, Greenbaum U, ramdial J, Alousi A, Joseph J, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Shpall E, Mehta R, Qazilbash M, Popat U, Oran B, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia. 2020 SOHO Virtual Meeting 20 Suppl 1:S202, 2020. e-Pub 2020.
44. Popat U, Mehta RS, Bassett Jr R, Olson A, Chen J, Ganesh C, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Daher M, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour SA, Rezvani K, Qazilbash MH, Molldrem J, Shpall EJ, Champlin RE, Andersson BS. Myeloablative fractionated busulfan conditioning regimen in older patients: results of a phase II study, 2020. e-Pub 2020.
45. Srour SA, Milton D, Bashir Q, Mehta R, Ciurea SO, Daher M, Popat U, Khouri I, Kebriaei P, Delgado R, Rondon G, Manasanch EE, Patel K, Lee HC, Shpall E, Orlowski R, Champlin R, Qazilbash MH. Survival trends in multiple myeloma after autologous hematopietic stem cell transplantation, 2020. e-Pub 2020.
46. Joseph J, Milton D, Chen J, Al-Atrash G, Alousi A, Bashir Q, Ciurea S, Daher M, Im J, R||B |, Olson A, Oran B, Saini N, Srour S, Andersson B, Champlin R, Popat U. Myeloablative fludarabine and busulfan regimen in myelofibrosis: long term outcomes and analysis of prognostic factors, 2020. e-Pub 2020.
47. Khouri I, Milton D, Ledesma C, Nastoupil L, Jabbour E, Anderlini P, Bashir Q, Daher M, Im J, Marin D, Mehta R, Olson A, Popat U, Qazilbash M, Samaniego F, Swaminathan I, Rondon G, Medeiros LJ, Gulbis A, Champlin R. Improved survival with non-myeloablative allogeneic transplantation (NMAT) compared to autologous stem cell transplantation (ASCT) for patients >60 years with relapsed follicular lymphoma (FL), 2020. e-Pub 2020.
48. Khouri I, Milton D, Wang Y, Ledesma C, Jabbour E, Swaminathan I, Anderlini P, Qaiser B, Daher M, Kebriaei P, Marin D, Mehta R, Olson A, Popat U, Srour S, Qazilbash M, Samaniego F, Fayad L, Nastoupil L, Im J, Flowers C, Rondon G, Champlin R, Gulbis A, Young K. Clinical relevance of MYC/BCL2, cell of origin and conditioning regimen in patients with relapsed diffuse large b-cell lymphoma (DLBCL) treated with allogeneic stem cell transplantation (ALLOSCT), 2020. e-Pub 2020.
49. Joseph J, Milton D, Chen J, Al-Atrash G, Alousi A, Bashir Q, Ciurea S, Daher M, Im J, Mehta R, Olson A, Oran B, Saini N, Srour S, Andersson B, Champlin R, Popat U. Myeloablative fludarabine and busulfan regimen in myelofibrosis: Long term outcomes and analysis of prognostic factors. ASCO20 Virtual Scientific Program 38(15_Supplemental):e19520, 2020. e-Pub 2020.
50. Popat U, Mehta RS, Bassett R, Olson A, Chen J, Ganesh C, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Sa S, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. 2020 TCT Meetings of ASTCT & CIBMTR 26(3, Supplement):S6-S7, 2020. e-Pub 2020.
51. Popat UR, Saliba RM, Mehta RS, Olson A, Chen J, Ganesh C, Woodworth G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour SA, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. 2020 TCT Meetings of ASTCT & CIBMTR 26(3, Supplement):S125, 2020. e-Pub 2020.
52. Kebriaei P, Banerjee PP, Ganesh C, Kaplan M, Nandivada V, Cortes AKN, Alousi AM, Marin D, Shpall EJ, Mehta RS, Ravandi F, Kantarjian H, Jabbour E, champlin RE, Rezvani K. Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. 2020 TCT Meetings of ASTCT & CIBMTR 26(3, Supplement):S102-S103, 2020. e-Pub 2020.
53. Srour SA, Milton DR, Bashir Q, Mehta RS, Saini N, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Delgado R, Rondon G, Manasanch E, Patel K, Lee HC, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. 2020 TCT Meetings of ASTCT & CIBMTR 26(3, Supplement):S238-S239, 2020. e-Pub 2020.
54. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi AM, Mehta RS, Oran B, Olson AL, Hosing C, Qazilbash MH, Khouri IF, ciurea SO, Shpall SO, Jorgensen JL, Wang SA, Jain N, Jabbour E, Kantarjian HM, Champlin RE, Konopleva MY, Kebrieaei P. Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. 61st ASH Annual Meeting and Exposition 134(Supplement_1):4598, 2019. e-Pub 2019.
55. Mukherjee A, Milton DR, Gulbis A, Ledesma C, Jabbour E, Alousi AM, Bashir Q, Daher M, Oran B, Olson AL, Marin D, Srour S, Kebriaei P, Mehta RS, Nemeth KP, Popat U, Im JS, Champlin RE, Khouri IF. Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Donor (MUD) Transplantation in Patients (pts) with Relapsed/Refractory Lymphoma. 61st ASH Annual Meeting and Exposition 134(Supplement_1):4530, 2019. e-Pub 2019.
56. Wang Y, Young KH, Milton DR, Ledesma C, Jabbour E, Xu-Monette ZY, Molldrem JJ, Anderlini P, Alousi AM, Bashir Q, Daher M, Fayad LE, Iyer SP, Kebriaei P, Marin D, Mehta RS, Olson AL, Popat U, Samaniego F, Westin JR, Qazilbash MH, Im JS, Rondon G, Gulbis A, Champlin RE, Khouri IF. Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation. 61st ASH Annual Meeting and Exposition 134(Supplement_1):2021, 2019. e-Pub 2019.
57. Oran B, Champlin RE, Wang F, Jeyakumar N, Garcia-Manero G, Kantarjian HM, Saliba RM, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi K. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. 61st ASH Annual Meeting and Exposition 134(Supplement_1):47, 2019. e-Pub 2019.
58. Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva M, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. 61st ASH Annual Meeting and Exposition 134(Supplement_1):42, 2019. e-Pub 2019.
59. Popat U, Saliba RM, Mehta RS, Olson AL, chen J, Ganesh C, Rondon G, Woodworrth G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. 61st ASH Annual Meeting and Exposition 134(Supplement_1):3296, 2019. e-Pub 2019.
60. Champlin RE, Popat U, Oran B, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Khouri IF, Hosing C, Anderlini P, Jones RB, Marin D, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Shpall EJ, Chen J, Rondon G, McMullin B, Al Jahdhami VP, Kawedia J, Valdez BC, Ma J, Thall PF, Andersson BS. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. 61st ASH Annual Meeting and Exposition 134(Supplement_1):257, 2019. e-Pub 2019.
61. Khouri IF, Milton DR, Ledesma C, Nastoupil LJ, Jabbour E, Anderlni P, Bashir Q, Ciurea SO, Daher M, Fayad LE, Im JS, Iyer SP, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash M, Srour S, Samaniego F, Rondon G, Medeiros J, Gulbis A, Champlin RE. Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL). 61st ASH Annual Meeting and Exposition 134(Supplement_1):322, 2019. e-Pub 2019.
62. Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, Bolanos-Meade J, Bredeson C, Copelan EA, George B, Gupta V, Kanakry CG, Mehta RS, Battiwalla M, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Tomlinson BK, Weisdorf DJ, Eapen M. Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor. 61st ASH Annual Meeting and Exposition 134(Supplement_1):3323, 2019. e-Pub 2019.
63. Popat U, Mehta RS, Bassett R, Olson AL, Chen J, Ganesh C, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash M, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. 61st ASH Annual Meeting and Exposition 134(Supplement_1):256, 2019. e-Pub 2019.
64. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta RS, Kaufman GP, Iyer WP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis. 61st ASH Annual Meeting and Exposition 134(Supplement_1):3198, 2019. e-Pub 2019.
65. Kebriaei P, Banerjee PP, Ganesh C, Kaplan M, Nandivada V, Cortes AKN, Alousi AM, Marin D, Shpall EJ, Mehta R, Ravandi F, Jabbour E, Kantarjian HM, Champlin RE, Rezvani K. Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. 61st ASH Annual Meeting and Exposition 134(Supplement_1):1298, 2019. e-Pub 2019.
66. Yalniz F, Saliba RM, Yucel OK, Garcia-Manero G, Ramdial J, Popat U, ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Hosing C, Marin D, Mehta R, Olson AL, Rezvani K, Shpall EJ, Rondon G, Champlin RE, Oran B. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. 61st ASH Annual Meeting and Exposition 134(Supplement_1):512, 2019. e-Pub 2019.
67. Kongtim P, Hasan O, Perez JMR, Varma A, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash MH, Mehta R, Shpall EJ, Alousi AM, Khouri IF, Kebriaei P, Popat UR, Champlin RE, Ciurea SO. Development and validation of a novel disease risk model for patients with AML receiving allogeneic hematopoietic cell transplantation. 2019 ASCO Annual Meeting 37(15_Supplemental):7016, 2019. e-Pub 2019.
68. Mehta R, Bassett R, Olson A, Chen J, Ganesh C, Alousi A, Anderlini P, Al-Atrash G, Bashir Q, Ciurea S, Hosing C, Im J, Jones R, Kebriaei P, Khouri I, Marin D, Molldrem J, Nieto Y, Oran B, Rezvani K, Qazilbash M, Srour S, Shpall E, Andersson B, Champlin R, Popat U. Post-Transplant Cyclophosphamide in HLA Matched and Haploidentical Transplant Recipients Receiving Myeloablative Timed Sequential Busulfan Conditioning Regimen: Results of a Phase II Study. 24th EHA Congress 3(S1):706, 2019. e-Pub 2019.
69. El Shazly M, Belal AA, Farouk M, Srour S, Popat U, Kebriaei P, Patel K, Mehta RS, Lee HC, Manasanch EE, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Impact of different maintenace therapy options after autologous hematopoietic stem cell transplantation in multiple myeloma at MD Anderson Cancer Center. 24th EHA Congress 3(S1):636-637, 2019. e-Pub 2019.
70. Mukherjee A, Milton DR, Jabbour E, Konopleva M, Dinardo CD, Gulbis A, Ravandi F, Daver NG, Kadia TM, Oran B, Popat UR, Ciurea SO, Im J, Kebriaei P, Mehta RS, Kantarjian HM, Champlin RE, Khouri IF. Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy. 2019 ASCO Annual Meeting 37(15_Supplemental):7047, 2019. e-Pub 2019.
71. Srour SA, Saliba R, Popat U, Oran B, Mehta R, Kebriaei P, Bashir Q, Olson A, Chen J, Hosing C, Khouri I, Qazilbash M, Shpall E, Champlin R, Ciurea S. Haploidentical transplantation for acute myeloid leukemia patients with detectable disease at transplant. 24th EHA Congress 3(S1):272, 2019. e-Pub 2019.
72. Rafei H, Fernandez-Vina M, Carmazzi Y, Moore B, Willis D, Basar R, Banerjee PP, Daher M, Hosing C, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Qazilbash MH, Shpall JE, Champlin RE, Marin D, Rezvani K, Cao K. Role of killer immunoglobulin-like receptor (KIR)-ligand interactions to prevent relapse in patients (pts) receiving matached unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML). 2019 ASCO Annual Meeting 37(15_Supplemental):7049, 2019. e-Pub 2019.
73. Khouri I, Milton D, Young K, Ledesma C, Alousi A, Bashir Q, Ciurea S, Im J, Marin D, Mehta R, Alatrash G, Molldrem J, Olson Am Oran B, Popat U, Qazilbash M, Rondon G, Nastoupil L, Samaniego F, Fayad L, Hagemeister F, Medeiros LJ, Champlin R, Gulbis A. Rituximab-beam and autologous stem cell transplant (ASCT) for patients (PTS) with relapsed follicular lymphoma (FL) not able to receive an allogeneic sct: 8-year median follow-up results. 24th EHA Congress 3(S1):720, 2019. e-Pub 2019.
74. Rafei H, Imahashi N, Basar R, Banerjee PP, Daher M, Ganesh C, Hosing C, Kaur I, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Spencer BP, Srour S, Shpall EJ, Champlin RE, Marin D, Rezvani K. Off-the shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients. 2019 ASCO Annual Meeting 37(15_Supplemental):7008, 2019. e-Pub 2019.
75. Popat UR, Mehta RS, Bassett R, Olson AL, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson B. Post-transplant cylcophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study. 2019 ASCO Annual Meeting 37(15_Supplemental):7007, 2019. e-Pub 2019.
76. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Molldrem JJ, Shpall EJ, Andersson BJ, Champlin RE, Popat UR. Myeloablative Conditioning Using Timed Sequential Busulfan in Older Patients with Acute Myeloid Leukemia: Long Term Results of a Prospective Phase II Clinical Trial. 2019 TCT Meetings of ASTCT & CIBMTR 25(3, Supplement):S116-S117, 2019. e-Pub 2019.
77. Srour SA, Milton DR, Bashir Q, Mehta RS, Delgado R, Rondon G, Nieto Y, Hosing CM, Popat UR, ciurea SO, Patel K, Lee HC, Manasanch E, thomas S, Weber D, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma. 2019 TCT Meetings of ASTCT & CIBMTR 25(3, Supplement):S21, 2019. e-Pub 2019.
78. Popat UR, Saliba RM, Olson A, Mehta RS, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Molldrem JJ, Nieto Y, Oran B, Qazilbash MH, Rezvani K, Rondon G, Shpall EJ, Varma A, Andersson BS, Champlin RE. Comparison of Tacrolimus and Post-Transplant Cyclophosphamide (PTCy) with Tacrolimus and Methotrexate (Tac/MTX) Gvhd Prophylaxis in Patients with AML Undergoing Transplantation from Matched Related or Unrelated Donors. 2019 TCT Meetings of ASTCT & CIBMTR 25(3, Supplement):S235-S236, 2019. e-Pub 2019.
79. Varma A, Abraham SC, Saini N, Bashir Q, Rondon G, Srour SA, Mehta RS, Olson A, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Shpall EJ, Champlin RE, Popat UR. Idiopathic Portal Hypertension Related Refractory Ascites (IPHRA) after Allogeneic Stem Cell Transplant. 2019 TCT Meetings of ASTCT & CIBMTR 25(3, Supplement):S144-S145, 2019. e-Pub 2019.
80. Saliba RM, Alousi AM, Andersson BS, chen J, Mehta RS, Molldrem JJ, Champlin RE, Popat UR. Higher Pre-Transplant IL-2 Levels Correlate with Higher Incidence of Acute Graft-Versus-Host Disease. 2019 TCT Meetings of ASTCT & CIBMTR 25(3, Supplement):S245, 2019. e-Pub 2019.
81. Patel B, Sheshadri A, Saliba RM, Rondon G, Ahmed T, Arain MH, Mehta RS, Popat UR, Hosing CM, Bashoura L, Dickey BF, Champlin RE, Alousi AM. Azithromycin Exposure Following Hematopoietic Stem Cell Transplantation Is Associated with an Increased Risk of Cancer Relapse in Acute Leukemia. 2019 TCT Meetings of ASTCT & CIBMTR 25(3, Supplement):S231-S232, 2019. e-Pub 2019.
82. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Oran B, Hosing C, Bashir Q, Olson AL, Nieto Y, Alousi AM, Kebriaei P, Srour SA, Mehta RS, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad LE, Lee HJ, Fowler NH, Parmar S, Westin JR, Hagemeister FB, Champlin RE, Ciurea SO. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. 60th ASH Annual Meeting and Exposition 132(Supplement 1):3356, 2018. e-Pub 2018.
83. Saini NY, Varma A, Ma J, Milton DR, Patel R, Hasan O, Bashir Q, Nieto Y, Mukherjee A, Delgado R, Rondon G, Popat U, Hosing C, Kebriaei P, Alousi AM, Ahmed S, Mehta RS, Ciurea SO, Khouri IF, Shpall EJ, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of t (11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. 60th ASH Annual Meeting and Exposition 132(Supplement 1):4607, 2018. e-Pub 2018.
84. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mukherjee A, Mehta RS, Khouri IF, Ciurea SO, Shpall EJ, Hasan O, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-Based Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population. 60th ASH Annual Meeting and Exposition 132(Supplement 1):4608, 2018. e-Pub 2018.
85. Khouri IF, Milton DR, Ledesma C, Erwin WD, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Im JS, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champlin RE, Medeiros J, Gulbis A. Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17-Year Experience. 60th ASH Annual Meeting and Exposition 132(Supplement 1):4651, 2018. e-Pub 2018.
86. Bannon S, Routbort M, Garcia-Manero G, Daver NG, Oran B, Borthakur G, Mehta RS, Naqvi K, Takahashi K, Alvarado Y, Kadia TM, Kantarjian HM, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. 60th ASH Annual Meeting and Exposition 132(Supplement 1):2667, 2018. e-Pub 2018.
87. Daher M, Cao K, Basar R, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Wang Q, Li L, Saliba RM, Pingali SRK, Popat U, Hosing C, Olson AL, Oran B, Mehta RS, Champlin RE, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation. 60th ASH Annual Meeting and Exposition 132(Supplement 1):2077, 2018. e-Pub 2018.
88. Lin P, Veltri LW, Rezvani K, Oran B, Ahmed S, Alatrash G, Mehta RS, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Jones RB, Qazilbash MH, Khouri IF, Shpall EJ, Champlin RE, Marin D. Allotransplants for Patients 65 years or Older with High-Risk Acute Myeloid Leukemia. 60th ASH Annual Meeting and Exposition 132(Supplement 1):4667, 2018. e-Pub 2018.
89. Popat U, Mehta RS, Bassett Jr RL, Olson AL, Chen J, Ahmed S, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson BS. Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Ha;oidentiacal Transplantation: Results of a Phase II Study. 60th ASH Annual Meeting and Exposition 132(Supplement 1):3373, 2018. e-Pub 2018.
90. Varma A, Saini NY, Sui D, Milton DR, Hasan O, Mukherjee A, Bashir Q, Rondon G, Srour SA, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS Khouri IF, Weber DM, Thomas SK, Manasanch EE, Lee HC, Patel KK, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. 60th ASH Annual Meeting and Exposition 132(Supplement 1):4609, 2018. e-Pub 2018.
91. Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva MY, Perez JMR, Elshazly M, Aljadayeh M, Alvarez M, Im JS, Alatrash G, Mehta RS, Popat U, Bashir Q, Oran B, Hosing C, Khouri IF, Kebriaei P, Champlin RE. Is a Matched Unrelated Donor Search Needed for All Allogeneic Transplant Candidates?. 60th ASH Annual Meeting and Exposition 132(Supplement 1):3450, 2018. e-Pub 2018.
92. Tabchi S, Nair R, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta, RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM). 2018 ASCO Annual Meeting 36(15_Supplemental):8044, 2018. e-Pub 2018.
93. Aboudalle I, Khan M, Feng L, Thomas SK, Manasanch EE, Patel KK, Medeiros LJ, Mehta R, Bashir Q, Qazilbash MH, Orlowski RZ, Weber DM, Hu S, Lee HC. Characteristics and outcomes of primary plasma cell leukemia in the era of novel agents; Single center experience. 2018 ASCO Annual Meeting 36(15_Supplemental):8054, 2018. e-Pub 2018.
94. Shah N, Mehta R, Li L, Mccarty J, Kaur I, Orlowski RZ, Cooper L, Lee DA, Cao K, Parmar S, Hosing C, Ahmed S, Nieto Y, Bashir Q, patel KK, bollard C, Qazilbash MH, Champlin RE, Rezvani K, Shpall EJ. Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma. 2018 ASCO Annual Meeting 36(15_Supplemental):8006, 2018. e-Pub 2018.
95. Popat U, Bassett R, Aung F, Valdez B, Ahmed S, Alousi A, Bashir Q, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash M, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson B, Champlin R. Eltrombopag to improve platelet recovery in haploidentical stem cell transplants (Haplo-SCT): Results of a Phase II Trial Plus a Comparison to Control Patients, 2018. e-Pub 2018.
96. Gowda L, Shah MV, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta RS, Weber D, Lee HC, Manasanch E, Shah AR, Thomas S, Parmar S, Nieto Y, Orlowski R, Champlin RE, Qazilbash MH. Primary Plasma Cell Leukemia: Stem Cell Transplant in an Era of Novel Induction Drugs. 2018 BMT Tandem Meetings 24(3, Supplement):S260-S261, 2018. e-Pub 2018.
97. Bashir Q, Milton D, Popat UR, Oran B, Nieto Y, Kebriaei, Ciurea SO, Ahmed S, Mehta RS, Olson A, Parmar S, Alatrash G, Hosing CM, Shah N, Patel K, Weber D, Thomas S, Manasanch E, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Maintenance Therapy in High-Risk Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. 2018 BMT Tandem Meetings 24(3, Supplement):S254, 2018. e-Pub 2018.
98. Shah MV, Saliba RM, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Ahmed S, Alousi AM, Mehta RS, Pemmaraju N, Verstovsek S, Popat UR. Transplant Outcomes for Patients with Secondary Acute Myeloid Leukemia (AML) Arising from Myeloproliferative Neoplasms (MPN). 2018 BMT Tandem Meetings 24(3, Supplement):S322-S323, 2018. e-Pub 2018.
99. Srour SA, Desai P, Ciurea SO, Bashir Q, Oran B, Olson A, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Alousi AM, Verstovsek S, Champlin RE, Popat UR. Immunosuppression Withdrawal is an Effective Treatment of Relapse after Allogeneic Stem Cell Transplant for Myelofibrosis. 2018 BMT Tandem Meetings 24(3, Supplement):S196-S197, 2018. e-Pub 2018.
100. Qazilbash MH, Milton DR, Bashir Q, Shah N, Nieto Y, Popat UR, Mehta RS, Kebriaei P, Delgado R, Rondon G, Weber D, Thomas S, Lee HC, Manasanch E, Patel K, Orlowski RZ, Champlin RE. Continuing Improvement in the Outcome of Patients with Multiple Myeloma Undergoing Auto-HCT Over Three Decades. 2018 BMT Tandem Meetings 24(3, Supplement):S50-S51, 2018. e-Pub 2018.
101. Claussen CM, Chuang T, Chaudhry M, Lee HC, Patel KK, Bashir Q, Parmar S, Ahmed S, Mehta RS, Thomas SK, Richards TA, Nieto Y, Shpall EJ, Qazilbash MH, Amini B, Davis RE. Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. 59th ASH Annual Meeting and Exposition 130(Supplement 1):4365, 2017. e-Pub 2017.
102. Li L, Muftuoglu M, h C, Mak D, Burks JK, Mehta RS, Xi Y, Lv J, Hu B, Jimenez J, Kaplan M, Shaim H, Imahashi N, Banerjee PP, Kerbauy LN, Mendt MC, FLWI L, Daher M, Depombo A, Basar R, Andreeff M, Wang J, Marin DC, Champlin RE, Shpall EJ, Rezvani K. NK Cell Diversity Influences Outcomes after Cord Blood Transplantation. 59th ASH Annual Meeting and Exposition 130(Supplement 1):1979, 2017. e-Pub 2017.
103. Mehta RS, Holtan SG, Wang T, Hemmer T, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Weisdorf DJ. Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Adults. 59th ASH Annual Meeting and Exposition 130(Supplement 1):517, 2017. e-Pub 2017.
104. Srour S, Desai P, Ciurea SO, Bashir Q, Oran B, Olson AL, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Verstovsek S, Champlin RE, Popat U. Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant. 59th ASH Annual Meeting and Exposition 130(Supplement 1):2007, 2017. e-Pub 2017.
105. Ciurea SO, Saliba RM, Chen J, Rondon G, Popat U, Parmar S, Anderson B, Alousi AM, Ahmed S, Bashir Q, Alatrash G, Hosing C, Olson AL, Mehta RS, Rezvani K, Shpall EJ, Khouri IF, Kebriaei P, Champlin RE. Allogeneic Transplantation for TP53+ AML: Prognostic Factors for Survival. 59th ASH Annual Meeting and Exposition 130(Supplement 1):1938, 2017. e-Pub 2017.
106. Gowda L, Saliba RM, Shah MV, Rondon G, Badar I, Olson AL, Ciurea SO, Kebriaei P, Srour SA, Parmar S, Nieto Y, Ahmed S, Mehta RS, Alatrash G, Marin DC, Andersson BS, Oran B, Bashir Q, Qazilbash MH, Hosing C, Khouri IF, Alousi AM, Anderlini P, Shpall EJ, Rezvani K, Champlin RE, Popat U. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival. 59th ASH Annual Meeting and Exposition 130(Supplement 1):3267, 2017. e-Pub 2017.
107. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Weisdorf DJ. Graft-Versus-Host Disease (GVHD)-Free Relapse-Free Survival (GRFS) and Chronic Gvhd (CRFS) in Alternative Donor Hematopoietic Cell Transplantation (HCT) in Pediatric Patients. 59th ASH Annual Meeting and Exposition 130(Supplement 1):2053, 2017. e-Pub 2017.
108. Mehta RS, Bejanyan N, Cao Q, Luo X, Brunstein C, Cooley S, Blazar BR, Weisdorf DJ, Wagner JE, Miller JS, Verneris MR. Immune Reconstitution after Umbilical Cord Blood Versus Peripheral Blood Progenitor Cell Transplantation in Adults Following Myeloablative Conditioning 128(22):2246, 2016. e-Pub 2016.
109. Bejanyan N, Brunstein CG, Cao Q, Mehta RS, Luo X, Curtsinger J, Cooley S, Blazar BR, Miller JS, Weisdorf D, Wagner JE, Verneris MR. Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (alloHCT): Comparing Results in Recipients of Unrelated Umbilical Cord Blood (UCB) to Those with an HLA-Matched Sibling Donor Peripheral Blood (MSD PB) 128(22):4590, 2016. e-Pub 2016.
110. Mehta RS, Wangen R, Cichocki F, Felices M, Luo X, Weisdorf DJ, Verneris MR, Miller JS, Cooley S. Adaptive NK Cell Expansion Is Associated with Reduced Relapse of Lymphoid Malignancies after Autologous Hematopoietic Cell Transplant 128(22):515, 2016. e-Pub 2016.
111. Mehta RS, Peffault de Latour R, DeFor TE, Robin M, Lazaryan A, Xhaard A, Bejanyan N, de Fontbrune FS, Arora M, Brunstein CG, Blazar BR, Weisdorf DJ, MacMillan ML, Socie G, Holtan SG. Improved Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) Associated with Bone Marrow as the Stem Cell Source in Adults. 2016 BMT Tandem Meetings 22(3, Supplement):S49, 2016. e-Pub 2016.
112. Lazaryan A, Bachanova V, Cao Q, McClune BL, Arora M, Mehta RS, Wagner JE, Brunstein CG, Weisdorf DJ, Bejanyan N. Reduced Intensity Versus Myeloablative Conditioning Allogeneic HCT for Relapsed/Refractory Lymphoma: Applying Refined Disease Risk Index (DRI) to Improve Survival. 2016 BMT Tandem Meetings 22(3, Supplement):S225-S226, 2016. e-Pub 2016.
113. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi AM, Qazilbash MH, Bashir Q, Ahmed S, Popat UR, Hosing CM, Shpall EJ, Champlin RE, Ciurea SO. Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation 126(23):3135, 2015. e-Pub 2015.
114. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi AM, Hosing C, Popat UR, Kebriaei P, Champlin RE, McNiece IK, De Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens 126(23):1190, 2015. e-Pub 2015.
115. Mehta RS, Chen X, Antony J, Szabolcs. Distinctions Between Effective and Ineffective AML-Specific Autologous Peripheral Blood (PB) Cytotoxic T-Lymphocytes (CTLs). 2015 BMT Tandem Meetings 21(2, Supplement):S190-S191, 2015. e-Pub 2015.
116. Mehta RS, Chen X, Antony J, Szabolcs P. Myeloid Derived Suppressor Cells (MDSC)-like Acute Myeloid Leukemia (AML) Cells Are Associated with Resistance to Cytotoxic Effects of Autologous (Auto) T-Lymphocytes (CTLs). 2015 BMT Tandem Meetings 21(2, Supplement):S191-S192, 2015. e-Pub 2015.
117. Mehta RS, Brammer J, Shpall EJ, Champlin RE. Acute Pulmonary Toxicity By Mycophenolate Mofetil (MMF) after Haploidentical Stem Cell Transplant (SCT) 124(21):5860, 2014. e-Pub 2014.
118. Mehta RS, Chen X, Jeyaraj A, Szabolcs P. Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLSs) 124(21):5806, 2014. e-Pub 2014.
119. Kumar R, Mehta RS, Zhou A, Smith RE. Outcomes Of Platelet Transfusion in Heparin Induced Thrombocytopenia Patients 122(21):2311, 2013. e-Pub 2013.
120. Mehta RS, Liman A, Passero VA, Liman AK. Lung Squamous Cell Carcinoma Metastatic To The Gastrointestinal Tract: Report Of Three Cases. Journal of Thoracic Oncology 7(9):S311, 2012. e-Pub 2012.
121. Cervoni-Curet FN, Milton DR, Garcia R, Hunter L, Ledesma C, Martinez CS, Rondon G, Carmazzi Y, Cao K, Al-Atrash G, Aljawai YM, Alousi AM, Bashir Q, Chen GL, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Smallbone P, Saini NY, Srour SA, Champlin RE, Flowers C, Shpall EJ, Fingrut WB. Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide (PTCy)-Based Graft-Versus-Host Disease Prophylaxis. TANDEM Meetings of ASTCT and CIBMTR 2025.
122. Lee CJ, Gooley TA, Onstad L, Carpenter PA, Mehta RS, Salit RB, Vo P, Krakow EF, Connelly-Smith L, Boiko JR, Lee SJ. Late Effects and Quality of Life in Long-Term Survivors Following Hematopoietic Cell Transplantation and Post-Transplantation Cyclophosphamide-Based GvHD Prophylaxis. TANDEM Meetings of ASTCT and CIBMTR 2025.
123. Mehta RS, Wang T, Schmidt G, Gadalla SM, Betts BC, Benjamin CL, Arrieta-Bolaños E, Bolon Y, Lee SJ. Choosing between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations. TANDEM Meetings of ASTCT and CIBMTR 2025.
124. Popat UR, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Allogeneic Stem Cell Transplantation in Very High-Risk AML/MDS: A Phase 2 Trial. TANDEM Meetings of ASTCT and CIBMTR.
125. Meyer EH, Srour SA, Oliai C, Hoeg RT, Gandhi AP, Muffly LS, Mehta RS, Waller EK, Lowsky R, Patel SS, Dholaria B, Pantin J, Salhotra A, McGuirk JP, Devine SM, Gomez-Arteaga A, Faramand R, Tamari R, Holter-Chakrabarty JL, Hamilton BK, Jimenez A, Pavlova A, Fernhoff NB, McClellan JS, Abedi M, Negrin RS. Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients. TANDEM Meetings of ASTCT and CIBMTR 2025.
126. Mehta RS, Sparapani R, Wang T, Spellman SR, Lee SJ, Petersdorf EW. Donor Age Matters for Patients Undergoing Haploidentical Donor HCT Even after Adjusting for HLA Factors. TANDEM Meetings of ASTCT and CIBMTR 2025.
127. Popat UR, Alousi AM, Bassett RL, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Shigle TL, Smallbone P. Jak Inhibitor Itacitinib with Ptcy and Tacrolimus to Prevent Gvhd in a Myeloablative Fractionated Busulfan Regimen: A Phase 2 Trial. TANDEM Meetings of ASTCT and CIBMTR 2025.
128. Aljawai YM, Smallbone P, Alousi AM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Kebriaei P, Marin D, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Impact of Donor Age and Donor-Recipient Sex Mismatch on Hematopoietic Cell Transplantation Outcomes. TANDEM Meetings of ASTCT and CIBMTR 2025.
129. Oshima MU, Mehta RS, Gooley TA, Cheng G, Ng K, Salit RB, Mielcarek M, Sandmaier BM, Carpenter PA, Vo P, Krakow EF, Connelly-Smith L, Boiko JR, Lee SJ, Lee CJ. Characterization of Chronic Graft-Versus-Host Disease Onset, Severity, and Treatment after Post-Transplantation Cyclophosphamide-Based Gvhd Prophylaxis. TANDEM Meetings of ASTCT and CIBMTR2025.
130. Kitko CL, Mehta RS, Popradi G, Olavarria E, Deeren D, Thomas B, Galvin J, Lou S, Radojcic V, Lee CJ. The Effects of Prior Lines of Therapy on Clinical Outcomes for Patients with Chronic Graft-Versus-Host Disease Receiving Axatilimab: A Post Hoc Analysis of Agave-201. TANDEM Meetings of ASTCT and CIBMTR 2025.

Book Chapters

1. Mehta, RS, Alousi, AM. Graft-Versus-Host Disease, 453-479, 2023.
2. Rafei, H, Mehta, RS, Oran, B, Rezvani, K, Shpall, E, Olson, AL. Umbilical Cord Blood Transplantation, 101-114, 2023.
3. Mehta, RS, Sheshadri, A, Alousi, AM. An Overview of Graft-Versus-Host Disease, 17-44, 2023.
4. Mehta RS, Weisdord D. History and Current Status of Hematopoietic Cell Transplantation. In: Hematopoietic Cell Transplantation for Malignant Conditions. Elsevier, 1-18, 2019.
5. Mehta RS, Shpall EJ. Ex vivo Cord Blood Manipulation: Methods, Data and Challanges. In: Cord Blood Transplantations (Advances and Controversies in Hematopoietic Transplantation and Cell Therapy) 1st ed, 2017.
6. Mehta RS, Brunstein C. Cord blood transplants versus other sources of allografts: Comparison of data in adult setting. In: Cord Blood Transplantations (Advances and Controversies in Hematopoietic Transplantation and Cell Therapy) 1st ed, 2017.
7. Mehta RS, Olson A, Ponce DM, Barker JN, Shpall EJ. Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. In: Hematology, Basic Principles and Practice 7e, 2017.
8. Metha RS, Rezvani I, Shpall EJ. Expanded Umbilical Cord Cells. In: Current Concepts and Controversies in Hematopoietic Cell Transplantation, 2016.
9. Mehta RS, Arnold R. Withholding and Withdrawing Life-Sustaining Therapies. In: Palliative Care: Core Skills and Clinical Competencies, 2nd Edition, 2011.

Letters to the Editor

1. Mehta, RS, Sparapani, R, Wang, T, Spellman, S, Lee, SJ, Petersdorf, EW. Donor Age Matters for Haploidentical HCT Patients Even After Adjusting for HLA Factors. American journal of hematology 100: 937-940, 2025.